Scripps Florida Scientists Identify Promising Drug Candidate to Treat Chronic Itch at Avoids Side Effects

Scripps Florida Scientists Identify Promising Drug Candidate to Treat Chronic Itch that Avoids Side Effects JUPITER, FL September 28, 2015 If you have an itch, you have to scratch it. But that's a problem for people with a condition called chronic intractable itch, where that itchy sensation never goes away a difficult-to-treat condition closely associated with dialysis and renal failure.

In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.

Our lab has been working on compounds that preserve the good properties of opioids and eliminate many of the side effects, said TSRI Professor Laura Bohn. The new paper describes how we have refined an aspect of signaling underlying how the drugs work at the receptor so they still suppress itch and do not induce sedation. Developing compounds that activate the receptors in this way may serve as a means to improve their therapeutic potential.

The study, which was published recently in the journal Neuropharmacology, used a compound called isoquinolinone 2.1 to target the kappa opioid receptor, which is widely expressed in the central nervous system and serves to moderate pain perception and stress responses.

The compound was effective in stopping irritant-induced itch, without causing sedation, in mouse models of the condition.

Bohn noted isoquinolinone 2.1 is one example of a new class of biased kappa agonists that avoid many central nervous system side effects by preferentially activating a G protein-mediated signaling cascade without involving another system based on -arrestin protein interactions.

The first author of the study, Investigation of the Role of Beta Arrestin2 in Kappa Opioid Receptor Modulation in a Mouse Model of Pruritus, was Jenny Morgenweck. Other authors include Kevin J. Frankowski, Thomas E. Prisinzano and Jeffrey Aub of The University of Kansas and the University of North Carolina-Chapel Hill. See http://www.sciencedirect.com/science/article/pii/S0028390815300721

The work was supported by the National Institutes of Health's National Institute on Drug Abuse (grant R01DA031927).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8136

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2015/20150928bohn.html...
	See more stories from scripps

Most recent headlines